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Summary: In 12 patients with severe Raynaud’s phenom­
enon (RP: ischemic ulcers or intractable pain despite use 
of narcotic analgetics), we studied the acute and long­
term hemodynamic effects of epoprostenol on systemic 
and finger skin circulation. Epoprostenol was infused in­
travenously (i.v., initial infusion rate of 2 ng/kg/min, with 
a subsequent increase of 2 ng/kg/min every 30 min to the 
individually tolerated maximal dose of 8 ng/kg/min) in a 
triple, 5-h, double-blind, placebo-controlled cross-over 
study. During epoprostenol infusion, systolic blood pres­
sure (SBP) remained stable, while diastolic BP (DBP) de­
creased ( — 8 mm Hg, p <  0.02), with a simultaneous in­
crease in heart rate (HR *f 14 beats/min, p < 0.001). 
Forearm blood flow (FBF) increased and forearm vascu­
lar resistance (FVR) decreased during epoprostenol as
compared with placebo infusion (p <  0.01). Epoprostenol 
caused a significant increase in fingertip skin temperature 
(p <  0.01) as well as in laser Doppler flux (p < 0.02) 
before and after a standardized cooling test of the hand as 
compared with placebo. The increase in transcutaneous 
oxygen tension reached significant difference only during 
recovery (p <  0.02). No long-term improvement was 
noted during two additional cooling tests performed 1 and
6 weeks after the completed epoprostenol or placebo tri­
ple-infusion cycle. Repeated long-lasting epoprostenol in­
fusion immediately improves the microcirculation, but 
these effects are not sustained after 1 week. Key Words: 
Epoprostenol—Raynaud’s phenomenon—Cooling test— 
Finger skin temperature—Laser Doppler flux.
Although the incidence of Raynaud's phenome­
non (RP) is —10-15% of the general population in 
the colder regions of the United States and northern 
Europe (1), relatively little is known about its un­
derlying pathophysiology (2), as is reflected by 
most experimental treatment protocols, resulting in 
some individual relief, but no major general im­
provement (2).
Prostacyclin [prostaglandin I2 (PGI2) or epopros­
tenol] is a potent vasodilator and platelet aggrega­
tion inhibitor (3), produced by intact blood vessel 
wall endothelium. Its mechanism of action depends 
on increase in cyclic AMP (4) through activated ad­
enylate cyclase (5). Depletion of prostacyclin might 
lead to vasospasm. Although this had never been 
shown to cause primary RP, endothelial dysfunc­
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tion seems probable in the secondary type (6). De­
spite its short half-life (t'A) of 2-3 min, prostacyclin 
has been reported to be effective for as long as 6 
weeks in RP in controlled and uncontrolled studies 
(7,8). To evaluate the acute and long-term efficacy 
of intravenously (i.v.) applied epoprostenol, we 
performed a double-blind, placebo-controlled 
study, using a standardized finger cooling test with 
microcirculatory measurements to evaluate the ef­
fect on cold-induced vasoconstriction in severe RP.
PATIENTS AND METHODS
Twelve nonsmoking patients with severe RP (i.e. either 
trophic skin lesions or pain that could not be sufficiently 
treated by morphinomimetics) were included in this ran­
sity Hospital, P.O. Box 9101, 6500 HB Nijmegen, The Nether­
lands.
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domized, double-blind, placebo-controlled cross-over 
study. Exclusion criteria were the current use of drugs 
that may affect RP or a myocardial infarction or ischemic 
stoke ^3  months before the start of the study. All patients 
gave written informed consent to the trial protocol, which 
was approved by the Ethical Committee, University Hos­
pital Nijmegen, According to the criteria of Allen and 
Brown (9) 2 patients were classified as having primary 
RP. The remaining 10 were diagnosed as having second­
ary RP due to connective tissue diseases according to 
American Rheumatism Association (ARA) criteria 
(10,11).
The study design consisted of an initial cycle with ei­
ther three epoprostenol or placebo infusions with an in­
terval of 1 week between infusions, followed by an
8-week washout period and the subsequent cross-over 
cycle (again with three infusion periods). Each infusion 
lasted 5 h, during which either the drug or placebo was 
administered through a catheter positioned in an antecu- 
bital vein.
The initial dosage of epoprostenol was 2 ng/kg/min, 
with increments of 2 ng/kg/min every 30 min to 8 ng/kg/ 
min or to the individually maximal tolerated dose. All 
tests were performed in a climate-controlled room (25°C) 
after a 30-min acclimatization period. The patients were 
asked not to consume alcohol for the 2 h before the tests 
and not to drink caffeine-containing beverages or to 
smoke for 24 h before the start of the experiment.
On the distal volar surface of the second, third, and 
fourth fingertip of the right hand, respectively, we mea­
sured Finger Skin Temperature (FST) in degrees centi­
grade by a thermocouple (Ellab Instruments), laser Dopp­
ler-estimated finger skin blood flux (LDF) in perfusion 
units (PU) by a periflux (Perimed) and transcutaneous 
oxygen tension (TcP02) in mm Hg by a Tacomette with 
the probe heated to ^45°C (Novametrix). LDF and 
TcP02 measurements were performed after calibration. 
After the infusion a 5-min occlusion period enabled us to 
substract the biological zero of the laser Doppler. Systolic 
and diastolic blood pressure (SBP and DBP in mm Hg) 
were registered by an automatic device (Arteriosonde, 
Roche) on the left upper arm, heart rate (HR, beats/min)
by ECG [in bpm and forearm blood flow (FBF) in ml/100 
ml/min] by strain-gauge venous occlusion plethysmogra­
phy (Loosco BVP96) with use of a wrist cuff. Mean ar­
terial BP (MAP) and forearm vascular resistance (FVR) 
were calculated by the formulas MAP = (SBP + 2 
DBP)/3 (in mm Hg) and FVR =* MAP/FBF (in AU).
To obtain a baseline value for each parameter we av­
eraged the first three values. Until the finger cooling test 
(FCT) was performed (after 90 min), all parameters were 
registered every 5 min. Subsequently, the right hand was 
immersed in a 16°C water bath for 5 min, with FST and 
T cP 02 measured every minute. During the first 20 min of 
recovery, FST, LDF, and T cP 0 2 were registered every 2 
min. BP and HR were measured every 15 min until the 
end of the experiment. Patients were instructed to report 
all side effects they experienced, and the infusion rate 
was reduced (or the infusion was discontinued) if neces­
sary. The long-term effect of epoprostenol on all param­
eters was evaluated by an additional FCT 1 and 6 weeks 
after both infusion cycles.
In the calculations, the average of each measured pa­
rameter during the (epoprostenol or placebo) infusions 
was used for statistical comparisons. To compare the ef­
fects of epoprostenol with those of placebo, we used the 
paired t test if the values were normally distributed; oth­
erwise, the paired Wilcoxon signed-rank test was used. 
All values are mean ± SEM.
RESULTS
The clinical characteristics of the 12 RP patients 
are shown in Table 1. The acute effect of intrave­
nous epoprostenol on BP, HR, FBF, and FVR are 
shown in Fig. 1. There were no significant differ­
ences in baseline values between epoprostenol and 
placebo.
During epoprostenol infusion, SBP decreased 
from 134 ± 7 to 127 ±  5 mm Hg (NS). DBP de­
creased from 77 ± 4 to 69 ±  3 mm Hg (p <  0.02). As 
a consequence, MAP decreased 8 mm Hg from 96 ±
4 to 88 ±  3 mm Hg (p <  0.05). HR increased from
TABLE 1. Clinical characteristics o f  i 2 RP  patients
Body mass^ Duration0 Nutritional^
Patient/age'Vsex index Diagnosis'7 of RP skîn lesions
1/45/F 19.7 PRP 6 —
2/43/F 23 SRP/PSS 13 Hh
3/79/F 17.5 SRP/VOD 26 +
4/43/M 24.3 SRP/PSS 16 +
5/60/F 22.5 SRP/PSS 16 +
6/45/F 23.8 SRP/PSS 26 ±:
7/29/F 21.5 SRP/UCTD 9 +
8/28/F 21.4 SRP/UCTD 12 +
9/5 8/F 24.5 SRP/PSS 32 +
10/24/M 22.4 PRP 2 —
11/58/F 19.9 SRP/PSS 4 +
12/36/M 20,3 SRP/PSS 19 +
a  Age and duration in years. 
b  Body weight (kg)/height2 (m).
c PRP, primary Raynaud’s phenomenon; SRP, secondary Raynaud's phenom­
enon; PSS, progressive systemic sclerosis; VOD, vascular occlusive disease; 
UCTD, undifferentiated connective tissue disease. 
d  No trophic skin lesions ( - ) ;  minor lesions (±); ulcers or gangrene ( + ),
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77 ±  3 to 91 ± 3  beats/min (p <  0.001). Epopros­
tenol did not affect FBF or FVR, although these 
differed significantly (p <  0.01) as compared with 
values in placebo-treated patients ( + 2 ml/100 ml/ 
min and — 9 AU, respectively).
The effects of epoprostenol infusion on the mi­
crocirculation (FST, LDF, and T cP02) are shown in 
Fig 2. Baseline microcirculatory values between 
epoprostenol and placebo did not differ signifi­
cantly.
Before the FCT, epoprostenol increased FST 
from 29,4° ±  1.2° to 32.1° ±  0.9°C (p <  0.02), with 
a significant final difference of 2.6°C as compared 
with placebo (p <  0.01). In contrast to placebo,
epoprostenol caused an increase in LDF from 14 ± 
3 to 23 ± 5 PU (p <  0.01), which was significantly 
greater than the value in placebo condition (p < 
0.01). No effect on TcP02 was observed.
During cooling, the decrease in all microcircula­
tory parameters was not significantly different in 
epoprostenol and placebo. During recovery, 
epoprostenol resulted in a complete microcircula­
tory recovery of FST from 20.6° ± 0.5° to 31.4° to
0.8°C (p <  0.01) and LDF from 11 ± 4 to 24 ± 5 PU 
(p <  0.01). During placebo, the increase was less for 
both (p <  0.01). The differences in TcP02 between 
epoprostenol and placebo reached significance only 
late during recovery (p < 0.02). As compared with
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FIG. 1. The effect of epoprostenol 
(solid line) and p lacebo infusion 
(dashed line) on systolic blood pres­
sure (SBP), diastolic blood pressure 
(DBP), heart rate (HR), mean arterial 
pressure (MAP), forearm blood flow 
(FBF), and forearm vascular resis­
tance (FVR) in time. All values are 
mean ±  SE.
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FIG. 2. The effect of epoprostenol (solid line) and placebo 
infusion (dashed line) on finger skin temperature (FST), laser 
Doppler flux (LDF), and transcutaneous oxygen tension 
(TcP02) in time. All values are mean ±  SE. The finger cooling 
test (FCT) was performed between T1 (after 90 min) and T2 
(black line).
placebo, epoprostenol improved neither the macro- 
nor the microhemodynamics, as determined by an 
additional FCT performed 1 and 6 weeks after the 
triple epoprostenol or placebo infusion cycle.
Side effects were reported during 88% of the 
epoprostenol infusions and in 5% of the placebo 
infusions. Most frequent were flushing (75%), head­
ache (56%), and palpitations (47%). Other com­
plaints were nausea, vomiting, dizziness, abdomi­
nal cramps, and retrosternal pain (without changes 
in ECG). In 9 of the 36 epoprostenol infusions, the 
infusion rate had to be reduced; the experiment had 
to be discontinued prematurely in 3. Patient 3 ex­
perienced temporary blurred vision, although oph­
thalmic examination showed no abnormalities. Pa­
tient 12 complained of retrosternal pain during all 
three epoprostenol infusions.
DISCUSSION
Theoretically, epoprostenol is expected to im­
prove the impaired microcirculation in patients with 
RP since it is a powerful vasodilator and platelet 
inhibitor. Indeed, our findings showed a pro­
nounced acute hemodynamic effect on the systemic 
circulation (increased FBF and HR, decreased BP 
and PVR) as well as on the microcirculation (in­
creased FST, LDF, and T cP 02) during epopros­
tenol infusion; an effect that was also observed pre­
viously in normal healthy volunteers (12). How­
ever, I week after the completed triple-infusion 
cycle, all of the cited signs of vasodilation and im­
provements in microcirculatory hemodynamics had 
already disappeared. This short-term effectiveness 
of epoprostenol is in agreement with its short tVi of 
2-3 min. The lack of long-term effects is in contra­
diction to results of several studies, although some 
studies report minor effectiveness (13). Belch and 
colleagues (7) reported that hand temperature in­
creased significantly 1 week after a triple 5-h 
epoprostenol infusion cycle (7.5 ng/kg/min) as com­
pared with placebo; for ^ 6  weeks, they noted a 
decrease in number and duration of attacks as well 
as healing of trophic skin lesions in the epopros- 
tenol-treated group. Dowd and associates (8) per­
formed an uncontrolled 72-h epoprostenol infusion 
(5-7 ng/kg/min) in patients who all had secondary 
RP (SRP) due to systemic sclerosis. For ^2 weeks 
after the infusion period, FST was significantly in­
creased. The mean duration of the subjective re­
sponse, as assessed by a diary, was 9 weeks. Rade- 
maker and co-workers (14) reported a long-term 
benefit of the more stable prostacyclin analogue il- 
oprost in SRP due to systemic sclerosis and sug­
gested that iloprost might heal endothelial lesions in 
systemic sclerosis, subsequently leading to de novo 
synthesis of epoprostenol. Fiessinger and col­
leagues (15) showed that iloprost was more effec­
tive than aspirin for relief of rest pain due to leg 
ischemia and healing of trophic lesions in patients 
with thromboangiitis obliterans.
During epoprostenol infusions, total skin blood 
flow as well as oxygen delivery to the skin im­
proved. TcP02 was measured to indicate skin oxy­
gen tension (16), thus representing capillary nutri­
tional skin flow (17). The LDF measurements are 
supposed to represent total skin blood flow, as well 
as that through part of arteriovenous shunts and the 
capillary loops (18,19). The laser Doppler technique
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measures the frequency shift of back-scattered laser 
light by moving erythrocytes in the outermost lay­
ers of the skin (19). Monitoring of LDF has proven 
to be of value in intervention studies (20,21). Its 
major disadvantage is the enormous inter- and in­
traindividual variation (22) caused by rapid sympa­
thetic reflex activity in thermoregulatory arteriove­
nous shunt flow (23). To reduce this variation, we 
averaged the three infusion series with either 
epoprostenol or placebo. Nevertheless, an obvious 
interindividual variation in LDF remained, shown 
by the SE. Many different measurement techniques 
(skin temperature, laser Doppler, finger BP, finger­
tip plethysmography, dynamic nailfold capillary mi­
croscopy) and provocation tests (local cold, contra­
lateral cooling, whole body cooling, postischemia 
hyperemia) are used to objectify vasospasm.
A standardized finger cooling test (24) was used 
as a model to mimic a Raynaud’s attack. Although 
obtaining the specific discolorations during local 
cold challenge of the hand is rarely possible, this 
FCT has been used successfully in several placebo- 
controlled therapeutic studies (20,21). In contrast to 
the cooling test used in the present study, most tests 
are not carefully standardized and their reproduci­
bility and diagnostic values have not been outlined. 
Yet other tests or measurement techniques could 
have yielded different results. Although all patients 
had severe RP, the heterogenicity of our patient 
population (2 primary RP and 10 secondary RP, 7 of 
whom had systemic sclerosis, and 2 of whom had 
unclassifiable autoimmune disease and 1 of whom 
had vascular occlusive disease) could have biased 
our study. The effects of intravenously adminis­
tered epoprostenol in one of these specific sub­
groups could not be analyzed.
In general, the side effects were dose dependent. 
Flush and headache occurred with 4 ng/kg/min, 
whereas palpitations, nausea and vomiting were 
noted in the 6-8-ng/kg/min range. The infusion rate 
had to be reduced in 9 patients; complaints usually 
disappeared after reduction. The total dosage used 
during all epoprostenol infusions in this study ap­
pears to be sufficient to obtain clinical effects if one 
considers the low (0.5 mg/kg/min for 6 h) dose that 
was effective in another study (25).
The term double-blind is a questionable one in 
studies like the present study. Because of the fre­
quent visible side effects (flushing) that occurred 
during epoprostenol infusion, both the physician 
and the patient were often aware of the identity of 
the drug used.
Although the patients were asked to keep a diary 
during and after the trial to note the number, sever­
ity, and duration of attacks, only 4 of them were 
able to record them reliably and fully during the 
3-month study period. Two patients obviously mis­
understood the meaning of the diary, and in 2 the 
number times duration of attacks often exceeded
the 24-h daily period. Therefore, the diary results 
were not analyzed. Epoprostenol benefits skin mi- 
crocirculatory flow during the infusion period, but 
these effects disappear soon after discontinuation of 
the infusion. Whether comparable agents with a 
longer tl/2 , such as iloprost, have a more prolonged 
circulatory and also subjective effect remains to be 
established. The development of oral analogues in 
the near future will be a major advance.
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